Skip to main content
. Author manuscript; available in PMC: 2009 Oct 23.
Published in final edited form as: Neuron. 2008 Oct 23;60(2):258–272. doi: 10.1016/j.neuron.2008.08.006

Figure 1. Bhlhb5 is Expressed in Post-Mitotic Excitatory Neurons of Developing Neocortex.

Figure 1

(A–J) HRP-immunocytochemistry for Bhlhb5 on coronal brain sections.

(A and B) At E12.5 (A) and E13.5 (B), Bhlhb5 is expressed in the cortical plate (CP) but not the ventricular zone (VZ).

(C and D) At E15.5 (C) and E17.5 (D), Bhlhb5 is strongly expressed in the CP, weakly expressed in the subventricular zone (SVZ), but not in the VZ.

(E–J) Bhlhb5 starts downregulating at the border of neocortex (NCX) and cingulate cortex (Cg) at P0 (E). At P4, downregulation proceeds into NCX anteriorly (F), and becomes more pronounced at the NCX-Cg border posteriorly (G,H). Bhlhb5 starts downregulating throughout the NCX by P7 (I) with markedly reduced expression by P14 (J). Black arrowheads in (E–H) mark extent of downregulation.

(K–M) Bhlhb5 does not colocalize with the S-phase marker BrdU (K; 30 min pulse), or the M-phase marker PH3 (L) in the VZ or SVZ (boxed region in C), but colocalizes with the post-mitotic neuronal marker, Tuj1 (M). Inset in (K) is magnified view of area adjacent to white arrowhead; shows lack of Bhlhb5 and BrdU colocalization in SVZ.

(N) Bhlhb5 is expressed by a subset of glutamatergic neurons.

(O) Bhlhb5 is not expressed by GABAergic interneurons.

LV, lateral ventricle. Scale bars: 250 µm (A–E), 500 µm (F–J), 50 µm (K, L, N and O), 25 µm (M). Inset in (K) not to scale.

HHS Vulnerability Disclosure